Rating neurologic impairment in multiple sclerosis

@article{Kurtzke1983RatingNI,
  title={Rating neurologic impairment in multiple sclerosis},
  author={John F. Kurtzke},
  journal={Neurology},
  year={1983},
  volume={33},
  pages={1444 - 1444}
}
  • J. Kurtzke
  • Published 1 November 1983
  • Medicine
  • Neurology
One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). [] Key Method A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5).

Tables from this paper

Historical and Clinical Perspectives of the Expanded Disability Status Scale
  • J. Kurtzke
  • Medicine, Psychology
    Neuroepidemiology
  • 2008
TLDR
Combination of the (Expanded) DSS and FS has been used successfully to assess impairment for natural history and treatment studies in MS.
Disability Rating Scales in Multiple Sclerosis
  • J. Kurtzke
  • Medicine, Psychology
    Annals of the New York Academy of Sciences
  • 1984
The International Federation of Multiple Sclerosis Societies has been attempting to define a Minimal Data Set for multiple sclerosis following the tripartite scheme of the World Health Organization,
The Disability Status Scale for multiple sclerosis
The Disability Status Scale (DSS),' with its associated Functional Systems (FS)2,3 and the latter's final revi- sions with the expanded DSS (EDSS)? has provided a system for encoding the neurologic
Scales for rating impairment in multiple sclerosis
TLDR
The Expanded Disability Status Scale (EDSS) has important flaws that seriously limit its usefulness, and the title is inappropriate in light of the widely accepted three-tier classification of dysfunction developed by the World Health Organization.
Clinical Outcome Measures for Multiple Sclerosis
TLDR
These rating scales illustrate the dichotomy between rating neurologic impairment, emphasizing mobility and scoring the formal neurologic examination, including reflexes and other elements not directly linked to impairment.
The MS impairment scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis
TLDR
The MSIS is easy to use and is robust to observer dissimilarities, it has a monomodal univariate distribution and has a better discriminatory power than the EDSS, especially in the E DSS range 6 - 9, while the interrater reliability is at least as good as that of the EdsS and the Al.
A comparison of two neurologic scoring instruments for multiple sclerosis
TLDR
It is found that the EDSS and SNRS were not strongly correlated within individual patients, contrary to expectation; moreover, in 9 of the 48 evaluable patients, the directions of their changes from baseline values were not mutually consistent and should be formally assessed in future clinical trials using these scales as outcome measures.
Integration of Cognitive Impairment in the Expanded Disability Status Scale of 215 Patients with Multiple Sclerosis
TLDR
A new cerebral functional system (NCFS) based on neuropsychological evaluation (NE) is proposed, including fatigue, and integrating grade 1 at EDSS, which was higher than the CFS and the E DSS and change in functional score was not correlated to current age or age at onset of MS.
Cognitive loss in multiple sclerosis. Case reports and review of the literature.
TLDR
Two new scales, a Cognitive Function Scale and a Frontal Release Scale, were adapted for the investigation of 12 patients with multiple sclerosis in whom cognitive disability was far greater than any other neurologic disability.
Self-Assessment of Neurologic Impairment in Multiple Sclerosis
TLDR
A self-assessed EDSS was developed in which MS patients evaluated their own level of disability and selected an overall score akin to that used by the physician, and a high degree of agreement was noted overall.
...
...

References

SHOWING 1-10 OF 20 REFERENCES
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
  • J. Kurtzke
  • Medicine, Psychology
    Acta neurologica Scandinavica
  • 1970
TLDR
It is concluded that as groups of MS patients worsen, they worsen in all areas, and any measure which will reflect even a part of this worsening will appear to be a valid estimate for the course of disease in groups of patients.
Further notes on disability evaluation in multiple sclerosis, with scale modifications
IN 1955 a disability status scale for multiple sclerosis was published that delineated 10 progressive steps or grades of overall neurologic dysfunction attributable to this disease.1 This was later
A New Scale for Evaluating Disability in Multiple Sclerosis
TLDR
The scale to be presented was devised to evaluate a possible therapeutic agent for multiple sclerosis and was used to measure status on admission to and discharge from the hospital in order to establish a baseline with which to compare the in-hospital course of groups of patients.
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
TLDR
Signs, symptoms, and laboratory findings were presented to describe an early bout of multiple sclerosis in a nationwide sample of males and provide the bases for later efforts to predict the course of illness for the persons affected.
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Rating schemes in multiple sclerosis (MS) have followed two separate pathways. One grouping is designed to define the nature and severity of the specific neurologic deficits found in MS, and may be
On the evaluation of disability in multiple sclerosis
TLDR
A quantitative evaluation of severity of the disease process two or more points in time could provide, for large groups under simultaneous evaluation, a reliable indication of the results of therapy.
Studies on the natural history of multiple sclerosis
TLDR
The U.S. Army experience in World War I was selected as the basis for a study of environmental and host factors of potentia1 etiologic significance in MS.
Isoniazid in treatment of multiple sclerosis.
• The clinical results of therapy with isoniazid for multiple sclerosis, while effecting subjective and objective improvement in a large percentage of cases, cannot be considered significant. New
THE SOCIO‐ECONOMIC SCALE
...
...